Pyxis Oncology, Inc. Lease, Cost
Pyxis Oncology, Inc. (PYXS) reported Lease, Cost of $988.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-13
- Pyxis Oncology, Inc. lease, cost for the quarter ending 2026-06-30 was $988.00K, a 4.08% decline year-over-year.
- Pyxis Oncology, Inc. lease, cost for the quarter ending 2026-03-31 was $926.00K, a 27.37% increase year-over-year.
- Pyxis Oncology, Inc. lease, cost for the quarter ending 2025-12-31 was $989.00K, a 7.40% decline year-over-year.
- Pyxis Oncology, Inc. lease, cost for the quarter ending 2025-09-30 was $975.00K, a 8.45% decline year-over-year.
- Pyxis Oncology, Inc. lease, cost for fiscal 2025 was $3.72M, a 15.76% decline from fiscal 2024.
- Pyxis Oncology, Inc. lease, cost for fiscal 2024 was $4.42M, a 12.74% increase from fiscal 2023.
- Pyxis Oncology, Inc. lease, cost for fiscal 2023 was $3.92M, a 3.65% increase from fiscal 2022.
- Pyxis Oncology, Inc. lease, cost for fiscal 2022 was $3.78M, a 417.81% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $988.00K 10-Q · filed 2026-08-13 | $1.91M 10-Q · filed 2026-08-13 | $2.90M derived: sum of 3 quarters · filed 2026-08-13 | $3.88M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $926.00K 10-Q · filed 2026-05-14 | $1.92M derived: sum of 2 quarters · filed 2026-05-14 | $2.89M derived: sum of 3 quarters · filed 2026-05-14 | $3.92M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $989.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.96M derived: sum of 2 quarters · filed 2026-03-23 | $2.99M derived: sum of 3 quarters · filed 2026-08-13 | $3.72M 10-K · filed 2026-03-23 |
| 2025-09-30 | $975.00K 10-Q · filed 2025-11-03 | $2.00M derived: sum of 2 quarters · filed 2026-08-13 | $2.73M 10-Q · filed 2025-11-03 | $3.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.03M 10-Q · filed 2026-08-13 | $1.76M 10-Q · filed 2026-08-13 | $2.83M derived: sum of 3 quarters · filed 2026-08-13 | $3.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $727.00K 10-Q · filed 2026-05-14 | $1.79M derived: sum of 2 quarters · filed 2026-05-14 | $2.86M derived: sum of 3 quarters · filed 2026-05-14 | $3.94M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $2.13M derived: sum of 2 quarters · filed 2026-03-23 | $3.21M derived: sum of 3 quarters · filed 2026-03-23 | $4.42M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.06M 10-Q · filed 2025-11-03 | $2.14M derived: sum of 2 quarters · filed 2025-11-03 | $3.35M 10-Q · filed 2025-11-03 | $4.26M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $1.07M 10-Q · filed 2025-08-14 | $2.28M 10-Q · filed 2025-08-14 | $3.19M derived: sum of 3 quarters · filed 2025-08-14 | $4.10M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.20M 10-Q · filed 2025-05-15 | $2.12M derived: sum of 2 quarters · filed 2025-05-15 | $3.02M derived: sum of 3 quarters · filed 2025-05-15 | $3.92M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $915.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.82M derived: sum of 2 quarters · filed 2025-03-18 | $2.72M derived: sum of 3 quarters · filed 2025-03-18 | $3.92M 10-K · filed 2025-03-18 |
| 2023-09-30 | $908.00K 10-Q · filed 2024-11-12 | $1.80M derived: sum of 2 quarters · filed 2024-11-12 | $3.00M 10-Q · filed 2024-11-12 | $4.16M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $893.00K 10-Q · filed 2024-08-14 | $2.10M 10-Q · filed 2024-08-14 | $3.25M derived: sum of 3 quarters · filed 2024-08-14 | $4.41M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.14M 10-Q · filed 2023-05-11 | $2.36M derived: sum of 2 quarters · filed 2024-03-21 | $3.51M derived: sum of 3 quarters · filed 2024-03-21 | $4.67M derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.37M derived: sum of 2 quarters · filed 2024-03-21 | $3.53M derived: sum of 3 quarters · filed 2024-03-21 | $3.78M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.15M 10-Q · filed 2023-11-07 | $2.31M derived: sum of 2 quarters · filed 2023-11-07 | $2.57M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $1.16M 10-Q · filed 2023-08-11 | $1.41M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $165.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $730.00K 10-K · filed 2023-03-22 | |||
| 2020-12-31 | $713.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |